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Distant metastasis is one of the most important determining factors
in the prognosis of colorectal cancer. Degradation of the extracel-
lular matrix that surrounds tumour cells is an essential step in the
processes of tumour invasion and metastasis. Matrix metallopro-
teinases (MMPs) degrade various components of the extracellular
matrix. In particular, MMP-2 (gelatinase A; also called type-IV
collagenase and 72-kDa gelatinase) degrades type IV collagen of
the basement membrane, as well as gelatin, and type V, VII and X
collagens (Collier et al, 1997). MMP-2 is expressed in different
types of human epithelial cancer, such as breast (Davies et al,
1993), ovarian (Naylor et al, 1994), pancreatic (Bramhall et al,
1996), and gastric (Sier et al, 1996) cancer, and its level seems to
be related to malignancy and invasion. The activity of MMP-2 is
modulated by a tissue inhibitor of metalloproteinase-2 (TIMP-2)
(Hayakawa, 1994; Stetler-Stevenson et al, 1993a). Moreover,
there have been several reports that the level of MMP-2 is not
related to malignancy and invasion (Visscher et al, 1994; Ring et
al, 1997) and that it is the level of TIMP-2 that is related to these
processes (Visscher et al, 1994; Ring et al, 1997; Murashige et al,
1996). These results contradict the original proposed functions of
MMP-2 and TIMP-2. In addition, membrane-type-1 matrix metal-
loproteinase (MT1-MMP) was recently identified (Sato et al,
1994). Conflicts among the above results might be resolved by
studies of the functional interplay between MT1-MMP, MMP-2
and TIMP-2. The primary aim of the present study was to investi-
gate whether the results of immunohistochemical detection of
MT1-MMP, MMP-2 and TIMP-2 in colorectal cancers might be
consistent with the proposed roles of these proteins in the promo-
tion of the metastatic behavior of tumours.
MATERIALS AND METHODS
Patients and tumour samples
A total of 92 adenocarcinomas of the colon and rectum were
studied. Tumours were obtained surgically between 1988 and
1993 at the Department of Surgery II, Oita Medical University.
There were 11 cases of simultaneous distant metastasis and nine
cases of allochronic distant metastasis. All specimens were fixed
in 10% buffered formalin and embedded in paraffin. The tumours
were staged according to the standard TNM classification (Sobin
and Wittekind, 1997).
Immunohistochemistry
For immunohistochemical analysis, 4 mm-thick sections were cut
from formalin-fixed, paraffin-embedded blocks and placed on
silan-coated slides. After deparaffinization, the sections were incu-
bated in 3% hydrogen peroxide for 20 min in order for devitaliza-
tion of the peroxidase. Deparaffinized and rehydrated specimens
were heated in 10 mM citrate buffer, pH 6.0, for 10 min in an auto-
clave at 121°C. After cooling to room temperature (RT) for 30
min, the specimens were incubated with normal rabbit serum for
15 min at RT. Then they were incubated with various primary
antibodies, namely, monoclonal antibody against MT1-MMP
(114–6G6, 1:25; Fuji Chemical Industries, Japan), monoclonal
antibody against MMP-2 (42-5D11, 1:100; Fuji Chemical
Industries) or monoclonal antibody against TIMP-2 (67-4H11,
1:100; Fuji Chemical Industries) for 16 h at 4°C. After incubation,
immunohistochemical staining was performed by the standard
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kit (Nichirei, Tokyo, Japan) and 3,3¢-diaminobenzidine as the
chromogen. Nuclei were counterstained with haematoxylin. For
evaluation of immunohistochemical staining, specimens were
divided into two groups as follows. The immunopositive cell area
was used for the evaluation of the immunohistochemical staining
of MT1-MMP, MMP-2 and TIMP-2 monoclonal antibody: nega-
tive, 0–10%; positive, > 10%. Expression of MMP-2 and TIMP-2
was also evaluated in terms of immunostaining of the tumour 
cell cytoplasm and the stroma. A clinicopathologic study was
performed by reference to the depth of invasion, lymphatic
invasion, venous invasion, lymph node metastasis, and distant
metastasis.
Statistical analysis
Correlations between the expression of each antigen and the
various clinicopathologic factors were examined by the c-squared
test, Fisher’s exact probability test and Mann-Whitney’s U-test.
Furthermore, correlations between the expression of pairs of anti-
gens were studied by the c-squared test.
RESULTS
Immunohistochemical staining of MT1-MMP, MMP-2
and TIMP-2
Immunohistochemical staining indicated that MT1-MMP was
localized predominantly in the tumour cell cytoplasm and it was
weakly or not expressed in normal tissue (Figure 1A). The
frequency of samples positive for MT1-MMP was 36% (33/92).
MMP-2 (Figure 1B) and TIMP-2 (Figure 1C) were localized by
immunostaining in the tumour cell cytoplasm and the stroma. The
frequency of samples positive for MMP-2 in the tumour cell cyto-
plasm was 20% (18/92) and in the stroma it was 30% (27/92).
Thirteen samples (14%) in 92 were positive for MMP-2 in both the
tumour cell cytoplasm and the stroma. The frequency for samples
positive for TIMP-2 in the tumour cell cytoplasm was 32% (29/92)
and in the stroma it was 47% (43/92). Eighteen samples (20%) in
92 were positive for TIMP-2 in both the tumour cell cytoplasm
and the stroma.
Correlations between the expression of each antigen
and the various clinicopathologic factors
Table 1 shows the correlations between the expression of each
antigen and the various clinicopathologic factors. The frequency
of immunodetection of MT1-MMP increased with increases in 
the depth of invasion (P = 0.007; Mann-Whitney U-Test). The
percentage of MT1-MMP-positive cases was significantly higher
in vascular invasion-positive cases (54%) than in invasion-
negative cases (29%; P = 0.02; c-squared test). The percentage of
cases positive for MMP-2 in the stroma was significantly higher in
vascular invasion-positive cases (42%) than in invasion-negative
cases (20%; P = 0.02; c-squared test). The frequency of detection
of TIMP-2 in the tumour cell cytoplasm increased with increases
in the depth of invasion (P = 0.03; Mann-Whitney U-test). TIMP-
2 was detected in the stroma more frequently in tumours with
lymphatic invasion and lymph node metastasis (P < 0.05; 
c-squared test) than in tumours without such features.
Correlations among antigens
The percentage of cases positive for MT1-MMP was significantly
higher in cases positive (61%, 11/18) for MMP-2 in the tumour
cell cytoplasm than in negative cases (30%, 22/74; P = 0.013; c-
squared test). The percentage of cases positive for MT1-MMP was
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Figure 1 Immunolocalization of MT1-MMP (A), MMP-2 (B) and TIMP-2 (C)
in samples of human colorectal carcinomas. Immunostaining was performed
with monoclonal antibodies raised against MT1-MMP, MMP-2 and TIMP-2 as
described in Materials and methods. Immunostaining revealed MT1-MMP is
in the cytoplasm of tumour cells (A), while MMP-2 (B) and TIMP-2 (C) were
immunostained in the tumour cell cytoplasm and the stroma, respectively
(original magnification ´ 400).
A
B
Csignificantly higher in cases positive (55%, 16/29) for TIMP-2 in
the tumour cell cytoplasm than in negative cases (27%, 17/63; 
P < 0.01; c-squared test). The percentage of cases positive for
MMP-2 in the tumour cell cytoplasm was significantly higher in
cases positive for TIMP-2 in the tumour cell cytoplasm (41%,
12/29) than in negative cases (10%, 6/63; P < 0.01; c-squared
test). The frequency of samples positive for all three (MT1-MMP,
MMP-2 and TIMP-2) was 12% (11/92), and the frequency of
samples negative for all three was 23% (21/92).
DISCUSSION
MMP-2, which is a type IV collagen-degrading enzyme, is a very
important factor in the infiltration and metastasis of several carci-
nomas. TIMPs are intrinsic inhibitors of MMPs and have been
studied clinically as potential carcinostatic agents (Watson et al,
1995; 1996; An et al, 1997). Theoretically, MMP-2 and TIMP-2
should be immunolocalized only in fibroblasts and monocytes at
the sites that produce MMP-2 and TIMP-2 (Poulsom et al, 1992;
Liabakk et al, 1996; Pyke et al, 1993; Ito et al, 1995). However,
they have also been immunolocalized in the cytoplasm and cell
membranes of cancer cells (Tomita and Iwata, 1996; Nomura et al,
1996; Höyhtyä et al. 1994). In our study, we found that MMP-2
and TIMP-2 were immunostained not only in the stroma of
tumours but also in the cytoplasm of cancer cells, as well as there
being elevated frequencies of expression of MT1-MMP, MMP-2,
and TIMP-2 in the cytoplasm of cancer cells. One reason for this is
that TIMP-2 and proMMP-2 might have been anchored to the cell
membrane by MT1-MMP (Sato et al, 1996; Imai et al, 1996).
Expression of MMP-2 was not strongly correlated with factors
related to infiltration apart from vascular invasion in our study.
One explanation of our results is that the immunostaining with the
MMP-2-specific antibody used in this study did not reflect the
activity of MMP-2 since the antibody recognized both MMP-2 and
proMMP-2 (Fujimoto et al, 1993). Furthermore, Liabakk et al
(1996) reported that less-advanced tumours at Dukes’ stage A
have higher levels of active MMP-2 than do more invasive
tumours at Dukes’ stage B. These results raise the possibility that
MMP-2 might be necessary while the tumour is in the process of
penetrating the bowel wall in tumours at Dukes’ stage A but might
be less important when tumours have spread beyond muscle into
the surrounding adipose tissue, as at stage B. Consequently, the
immunohistochemical detection of MMP-2 appears not to be an
appropriate indicator of infiltration and metastasis in a clinical
setting.
The expression of TIMP-2 has been reported to be closely corre-
lated with the progression of human colorectal cancer, a proposal
that conflicts with the original function of TIMP-2 as an inhibitor
of MMPs (Murashige et al, 1996; Tomita and Iwata, 1996). In our
study, expression of TIMP-2 in the tumour cell cytoplasm was
correlated with depth of invasion and expression of TIMP-2 in the
stroma was correlated with lymphatic invasion and lymph node
metastasis. These results indicate that TIMP-2 is a reliable indi-
cator of the progression of human colorectal carcinoma. These
results are in conflict with the original proposed functions of
inhibitors of MMPs for the following reasons. TIMPs counteract
the proteolytic functions of MMPs in a stoichiometric manner, at a
ratio of 1:1 (Stetler-Stevenson et al, 1993b). However, the pres-
ence of excess TIMPs, as compared to MMPs, in tumour tissue
might indicate that an abnormal ratio in tumour tissue was associ-
ated with growth and metastasis, and the binding and biological
actions of MMPs and TIMPs might be altered in the presence of
excess TIMPs (Tomita and Iwata, 1996; Kossakowska et al, 1996).
In addition, the TIMP-2-specific antibody used in our study also
recognized the proMMP-2/TIMP-2 complex (Höyhtyä et al,
1994). TIMP-2 in this complex functions as an activator of
proMMP-2. Accordingly, under difficult circumstances, such as
when quantifying TIMP-2 and MMP-2, immunohistochemical
detection of TIMP-2 might indicate that TIMP-2 is essential for
the activation of proMMP-2.
Recently, MT1-MMP was identified in the cell membranes of
transfected cells that expressed MT-MMP and the expression of
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Table 1 Correlations between the expression of MT1-MMP, MMP-2 and TIMP-2 and clinicopathologic factors
MT1-MMP MMP-2 TIMP-2
Tumour cell Stroma Tumour cell Stroma
cytoplasm cytoplasm
Variable Positive P value Positive P value Positive P value Positive P value Positive P value
rate (%) rate (%) rate (%) rate (%) rate (%)
Depth of invasiona
T1 6 0.007 28 NS 28 NS 28 0.03 39 NS
T2 36 7 25 11 46
T3 and T4 48 24 33 46 50
Lymphatic invasionb
Positive 44 NS 19 NS 44 NS 33 NS 58 0.04
Negative 29 20 29 31 37
Venous invasionb
Positive 54 0.02 15 NS 42 0.02 42 NS 62 NS
Negative 29 21 20 27 41
Lymph node metastasisb
Positive 34 NS 14 NS 37 NS 34 NS 60 0.046
Negative 37 23 25 30 39
Distant metastasisb
Positive 45 NS 15 NS 20 NS 40 NS 35 NS
Negative 33 21 32 29 50
NS, Not significant; aMann-Whitney’s U-test; bchi-squared test or Fisher’s exact probability testMT1-MMP induced the activation of the precursor to MMP-2,
proMMP-2 (Sato et al, 1994). There were few previous reports of
immunohistochemical detection of MT1-MMP in colorectal carci-
noma. In tumour cells of invasive lung carcinomas, MT1-MMP
was immunolocalized in the carcinoma cells but not in the
parenchymal or stromal cells of the surrounding normal tissue
(Sato et al, 1994). In gastric carcinoma, MT1-MMP was predomi-
nantly immunolocalized in the carcinoma cells, and some carci-
noma cells showed immunostaining on the cell membrane
(Nomura et al, 1995). We found that MT1-MMP was immunolo-
calized predominantly in colorectal carcinoma cells, while its
levels were low or it was absent in normal tissue. Moreover,
expression of MT1-MMP was correlated with vascular invasion in
cases of gastric carcinoma (Nomura et al, 1995) and with lymph
node metastases in cases of lung carcinoma (Tokuraku et al, 1995)
in previous studies. The present study showed that expression of
MT1-MMP was correlated with vascular invasion and the depth of
invasion. These results suggest that the expression of MT1-MMP
might reflect infiltration in colorectal carcinoma.
Thus, immunohistochemical detection of MT1-MMP and
TIMP-2 provides appropriate indices of infiltration but expression
is not correlated with distant metastases in colorectal carcinoma.
Our results indicate that not only MMPs but also other factors are
required for the development of distant metastases.
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